AMA opposes BTC class
This article was originally published in The Tan Sheet
The American Medical Association reaffirms its stance against a formal behind-the-counter drug class under consideration by FDA (see story, p. 5). A resolution introduced by AMA's Michigan delegation cites BTC prescribing as potentially "out of the realm of a pharmacist's training," which "might affect patient safety and quality of care." The AMA House of Delegates, which held its annual meeting June 15, did not pass the resolution because the association in 1984 adopted a policy opposing "a third transitional class of drugs." AMA questions FDA's authority to create a third drug class (1"The Tan Sheet" Nov. 19, 2007, p. 4)...
You may also be interested in...
There is one thing agreed on by opponents and proponents of assigning drugs to behind-the-counter status, including representatives from the pharmaceutical industry, drug retailers, the pharmacy and medical professions, researchers and consumer advocates: FDA will need a long time to reach a decision on the issue, they say
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.